Allogeneic Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: Results from the MANTLE-FIRST Study on Behalf of Fondazione Italiana Linfomi

Investigators retrospectively analyzed 55 patients who underwent llogeneic stem cell transplantation for mantle cell lymphoma relapsed or refractory after rituximab and high-dose cytarabine within the MANTLE-FIRST project.
[Leukemia & Lymphoma]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Sutro Biopharma and BioNova Pharmaceuticals Enter into Collaboration for STRO-001 in Greater China

Sutro Biopharma, Inc and BioNova Pharmaceuticals Limited announced an option agreement for BioNova to develop and commercialize STRO-001, a CD74-targeting Antibody-Drug Conjugate, for patients with hematologic cancers, in Greater China, including mainland China, Hong Kong, Macau and Taiwan.
[Sutro Biopharma, Inc.]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

CAR-T Cell Therapy in T Cell Malignancies: Is Success a Low-Hanging Fruit?

Investigators highlight the preclinical and clinical efforts made for addressing these drawbacks and also review additional potent stratagems that could improve CAR-T therapy in T cell malignancies.
[Stem Cell Research & Therapy]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

ASTCT, CIBMTR, and EBMT Clinical Practice Recommendations for Transplant and Cellular Therapies in Mantle Cell Lymphoma

The ASTCT, CIBMTR, and the EBMT, jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-, allo-hematopoietic cell transplantation, and chimeric antigen receptor T-cell therapy for patients with newly diagnosed and relapsed/refractory mantle cell lymphoma.
[Bone Marrow Transplantation]
[zotpress userid=” items=’TNY3R799′ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Response and Resistance to CDK12 Inhibition in Aggressive B-Cell Lymphomas

By implementing pharmacogenomics and a cell-based drug screen, scientists found that THZ531 led to inhibition of oncogenic transcriptional programs, especially the DNA damage response pathway, MYC target genes and the mTOR-4EBP1-MCL-1 axis, contributing to dramatic lymphoma suppression in vitro.
[Haematologica]
[zotpress userid=’7992332′ items=’WDPPBB64′ style=’apa’ cite=’yes’]
AbstractFull Article
Bookmark

No account yet? Register

Share

Zanubrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase I/II study in patients with various B-cell malignancies. Zanubrutinib was well tolerated and demonstrated activity in patients with relapsed/refractory mantle cell lymphoma.
[Blood Advances]
[zotpress userid=’7992332′ items=’N56VHKD3′ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Activity of Immunoproteasome Inhibitor ONX-0914 in Acute Lymphoblastic Leukemia Expressing MLL–AF4 Fusion Protein

Researchers found that acute lymphoblastic leukemia cells expressing MLL–AF4 fusion protein expressed high levels of lymphoid tissue-specific immunoproteasomes and were sensitive to pharmacologically relevant concentrations of specific immunoproteasome inhibitor ONX-0914.
[Scientific Reports]
[zotpress userid=” items=’KMES6PHA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Longitudinal Single-Cell Profiling Reveals Molecular Heterogeneity and Tumor-Immune Evolution in Refractory Mantle Cell Lymphoma

The authors characterized the cellular and molecular heterogeneity within and across patients and delineate the dynamic evolution of tumor and immune cell compartments at single cell resolution in longitudinal specimens from ibrutinib-sensitive patients and non-responders.
[Nature Communications]
[zotpress userid=” items=’MT8ZC3A7′ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

P300/CBP Inhibition Sensitizes Mantle Cell Lymphoma to PI3Kδ Inhibitor Idelalisib

Scientists report that a p300/CBP inhibitor, A-485, could overcome resistance to idelalisib in mantle cell lymphoma cells in vitro and in vivo.
[Acta Pharmacologica Sinica]
[zotpress userid=’6445212′ items=’SBHNB93Q’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Ciclopirox and Bortezomib Synergistically Inhibits Glioblastoma Multiforme Growth via Simultaneously Enhancing JNK/p38 MAPK and NF-κB Signaling

Investigators showed that ciclopirox (CPX) displayed strong anti-tumorigenic activity on glioblastoma multiforme (GBM). Mechanistically, CPX inhibited GBM cellular migration and invasion by reducing N-Cadherin, MMP9 and Snail expression.
[Cell Death & Disease]
[zotpress userid=’6807162′ items=’SE858ELT’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Epcoritamab Induces Potent Anti-Tumor Activity against Malignant B-Cells from Patients with DLBCL, FL and MCL, Irrespective of Prior CD20 Monoclonal Antibody Treatment

Researchers assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from newly diagnosed and relapsed/refractory B-cell non-Hodgkin lymphoma patients.
[Blood Cancer Journal]
[zotpress userid=’6445218′ items=’RALZVNEA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share
Share